Dulaglutide is a synthetic GLP-1 receptor agonist fused to the human IgG4 Fc domain, widely used in preclinical research to investigate prolonged receptor activation, albumin-independent half-life extension, modulation of beta-cell function, and related cellular mechanisms. This research-grade peptide is produced under stringent GMP-compliant conditions and provided as a lyophilized powder to ensure superior purity, stability, and reliability in experimental applications.
Engineered solely for preclinical investigations, each batch of Dulaglutide undergoes a comprehensive quality assessment and includes complete documentation, including a Certificate of Analysis (COA), purity data, and structural verification.
Scientific Overview
Dulaglutide binds GLP-1 receptors with high affinity, resisting DPP-4 degradation and enabling once-weekly activity in research settings. Preclinical investigations demonstrate Dulaglutide’s utility in the following research areas:
- Glucose-dependent insulin secretion and suppression of glucagon in pancreatic models
- Delay of gastric emptying and modulation of postprandial glucose excursions
- Examination of central GLP-1 receptor pathway signaling mechanisms
- Enhancement of beta-cell survival and proliferation markers in islet studies
- Modulation of cardiometabolic parameters in preclinical in vivo models
Why Researchers Choose Our Dulaglutide
For laboratories requiring dependable Dulaglutide research peptide, our manufacturing process prioritizes reproducibility and scientific precision. Every batch is confirmed for:
- Purity ≥99% by HPLC
- Structural identity via mass spectrometry
- Third-party Certificate of Analysis (COA) available per lot
For Research Use Only. Not for human use.
This product is intended strictly for laboratory and research purposes. It is not intended for use in humans or animals, and is not a drug, medicine, or dietary supplement.
Explore our testing protocols in About Peptides > Rigorous Testing.
Research-Referenced Functional Attributes (Based on existing preclinical and literature data — not intended as claims of therapeutic use)
- Sustained GLP-1 receptor activation due to Fc fusion and resistance to DPP-4 in rodent models
- Glucose-dependent enhancement of insulin secretion and glucagon suppression in pancreatic beta-cell cultures
- Examination of central GLP-1 receptor signaling pathways in preclinical models
- Protection of pancreatic islets from glucotoxicity and lipotoxicity in vitro
- Modulation of gastrointestinal motility and nutrient absorption dynamics in metabolic models
- Examination of Fc-mediated pharmacokinetics supporting extended duration in vivo
